Analyst thinks RSV vaccine market could reach over USD 10bn
Glaxosmithkline, Johnson & Johnson and Pfizer are likely to win big on the sale of RSV vaccines, but Bavarian Nordic could also profit nicely off the billion-dollar market, analyst at investment bank Leerink assesses.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
As companies move closer to completing a vaccine against the respiratory syncytial virus, a potentially very lucrative new market begins to emerge. It could even reach a size of USD 10.5bn in the next decade, estimates analyst at SVB Leerink Geoffrey Porges, according to Fiercepharma.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer begins phase III trial for vaccine against RSV
For subscribers
